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We  report  the  case  of  a  51-year-old  gentleman  with  previously  diagnosed  gastrointestinal  stromal  tumor
(GIST)  of  the  rectum  with  metastasis  to  the penis.  The  patient  underwent  abdominoperineal  resection
of  the  primary  tumor  with  negative  margins  and  completed  a three-year  course  of imatinib  mesylateeywords:
astrointestinal stromal tumor (GIST)
ectal
etastasis
enile
(Gleevec).  Forty  months  after  resection  of  his rectal  tumor,  the patient  presented  to his urologist  with
worsening  testicular  pain,  mild  lower  urinary  tract  obstructive  symptoms,  and  nocturia.  A pelvic  MRI
revealed  the  presence  of an  ill-deﬁned  mass  in  the  right  perineum  extending  from  the  base  of  the  penis
to the  penoscrotal  junction.  Biopsy  of this  mass  was  consistent  with  metastatic  GIST.  To  our knowledge,
this  is  the  ﬁrst  report  of  metastatic  GIST  to the  penis.
Published  by  Elsevier  Ltd on  behalf  of  IJS  Publishing  Group  Ltd. This is an  open  access  article  under
he CCt
. Introduction
Gastrointestinal stromal tumors (GIST) are mesenchymal neo-
lasms that account for approximately 1–3% of all malignant
astrointestinal tumors [1]. Clinical characteristics of the tumor
re dependent on the anatomic location, size, and aggressive-
ess of the tumor. Primary GISTs originate most commonly in the
tomach [2], but primary GISTs arising from the pleura, retroperi-
oneum, omentum, and mesentery have also been reported [3].
ISTs typically metastasize to intra-abdominal locations, with com-
on  metastatic sites being the liver, omentum, and the peritoneal
avity [4]. Metastasis of GISTs to lymph nodes and extra-abdominal
ites via lymphatics is rare [5].
Imatinb mesylate (Gleevec) has proven to be a safe and efﬁca-
ious adjunct in the treatment of KIT (CD117)-positive GISTs and
as been used for the last 15 years for the treatment of metastatic
ISTs [6,7]. A literature review of the metastatic potential of GISTs
dentiﬁed one case of a “lump at the base of the penis” thought
o be a metastatic lesion arising from a primary rectal tumor [8].
lthough there have been no reported cases of metastatic GIST to
he corpora of the penis, cases of GIST metastases to the prostate
rom primary rectal tumors are documented [9–11]. In this report,
e describe the ﬁrst documented case of metastatic GIST to the
enis.∗ Corresponding author at: 623 N. Pierce St., Little Rock, AR 72205, United States.
E-mail addresses: jcarlson@uams.edu, JCarlson@uams.edu (J. Carlson),
MAlobuia@uams.edu (W.  Alobuia), JSMizell@uams.edu (J. Mizell).
ttp://dx.doi.org/10.1016/j.ijscr.2016.11.006
210-2612/Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open a
y-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2. Presentation of case
A 51-year-old Caucasian male was found to have a 6.5 × 6 cm
rectal mass just proximal to the sphincter complex on screening
colonoscopy. Biopsy of the mass demonstrated GIST with mitotic
ﬁgures. The patient was started on neoadjuvant imatinib therapy
to downstage the tumor prior to surgical resection. Four months
after initiating treatment, an MRI  of the pelvis revealed excel-
lent response to imatinib, as the rectal mass had reduced in size
to 3.8 × 3.1 × 2.2 cm.  After a total of eight months of neoadju-
vant imatinib therapy, the patient underwent an abdominoperineal
resection (APR). The patient did well peri-operatively. Pathol-
ogy of the surgical specimen revealed a gastrointestinal stromal
tumor 2.8 cm in greatest extent, 80–90% hyalinization with scarce
cellularity (Figs. 1 and 2). The lesion involved the mucosa, submu-
cosa, muscularis propria, and perirectal soft tissue. Mitotic rate of
<1/50hpf was  visualized. Perineural invasion was identiﬁed, but
lymphovascular invasion was  not. Negative margins were attained,
and eleven of eleven lymph nodes collected were negative for
malignancy. Imatinib therapy was continued postoperatively.
One year after APR, a surveillance colonoscopy was performed,
and no recurrent or metachronous lesions were found. The patient
was followed with imaging studies every six months. CT scans of the
abdomen and pelvis obtained over following three years revealed
no evidence of intra-abdominal or pelvis abnormalities or evidence
of recurrent or metastatic disease. Imatinib was discontinued after
a total of three years of treatment.
Three and a half years after APR, the patient presented with
complaints of obstructive urinary symptoms, erectile dysfunction,
and progressively worsening testicular pain radiating towards his
rectum. A physical examination identiﬁed no gross lesions of the
ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Fig. 1. Microscopic analysis of the rectal GIST. Tumor cells are spindled, forming
fascicles with increased mitotic rate.
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Fig. 3. Axial view of pelvis MRI. Axial view of the pelvis on MRI  revealed a right
corpus cavernosum mass.
Fig. 4. Sagittal view of pelvis MRI. MRI  of the pelvis demonstrated the right cor-
pus cavernosum mass causing external compression of the urethra, leading to the
patient’s lower urinary tract obstructive symptoms.ig. 2. Microscopic analysis of the rectal GIST. The tumor demonstrates large areas
f  hyalinization secondary to therapy with imatinib.
enis. A CT scan of the abdomen and pelvis was unremarkable,
nd cystoscopy showed no evidence of obstruction or abnormal-
ty of the urethra or bladder. The patient was treated for suspected
pididymitis vs. prostatitis.
The patient continued to experience worsening right testicu-
ar, right hip, and perineal pain, which was moderately relieved
y application of a heating pad and sitz baths but not by narcotic
ain medication. On examination, the proximal penile shaft was
ender to palpation, and an ill-deﬁned mass was  noted in the right
erineum extending from the base of the penis to the penoscro-
al junction. A pelvic MRI  revealed an 8.4 × 4.3 × 3.6 cm enhancing
ass in the right corpus cavernosum (Figs. 3 and 4). The patient
as referred to Urologic Oncology. Needle biopsies of the penile
esion were obtained, and histologic evaluation of these specimens
evealed a cellular spindle cell tumor with mitoses, positive CD117
mmunostain, and negative for desmin, ﬁndings which are consis-
ent with metastatic GIST.
Medical and surgical options were discussed with the patient,
ho opted to continue imatinib therapy, as opposed to under-
oing surgery. Three months after resuming imatinib, the patient
eported decreased perineal pain and ability to obtain an erection
ith the use of a vacuum device. Four months after resuming ima-
inib, an MRI  of the pelvis demonstrated that the metastatic penile
esion had decreased in size (Fig. 5). The patient was then recep-
ive to undergo surgical resection of the right corpus cavernosum.
athological examination of the excised tumor revealed metastatic
Fig. 5. Axial view of follow-up MRI. MRI  of the pelvis obtained four months after
resuming imatinib demonstrated decrease in the size of the right corpus cavernosum
mass from 8.4 × 4.3 × 3.6 cm to 4.9 × 1.8 × 1.5 cm.
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IST with lymphovascular invasion identiﬁed, 94 mitoses/50hpf,
nd positive margins. Imatinib was continued post-operatively.
One month after corpus cavernosum resection, the patient
egan to experience worsening positional right hip pain that radi-
ted to his right knee. Despite continued use of imatinib, repeat
RI  of the pelvis three months after metasetectomy demonstrated
esions within the left corpus cavernosum concerning for persis-
ent metastatic disease. Sunitinib was substituted for imatinib at
hat time. An MRI  of the pelvis obtained six months after metastec-
omy demonstrated further progression in the number and size of
he lesions within the left corpus cavernosum, as well as a lesion in
he right ischium concerning for osseous metastasis. Core biopsy of
he right ischial lesion was consistent with a poorly differentiated
etastatic carcinoma. The malignant cells were strongly positive
or cytokeratin AE1/AE3, but negative for Ckit (CD 117) and S-
00. Further analysis of the biopsy sample revealed that the lesion
ontained an exon 11 mutation, suggesting that the lesion was  con-
istent with metastatic GIST to the right ischium. PET CT imaging
lso identiﬁed tumor in the left ischiorectal fossa. Transitioning
rom sunitinib to regorafenib was recommended.
. Discussion
For patients presenting with metastatic GIST, the median sur-
ival is reported to be 19 months [12]. The treatment of metastatic
IST depends on the size, location, and extent of the metastatic
esions and may  incorporate both medical and surgical interven-
ion. First-line medical treatment with imatinib for patients with
etastatic GIST yields regression or stabilization of disease in ∼80%
f patients [13]. However, despite the initial response to imatinib
een in most patients with metastatic GIST, a signiﬁcant portion of
hem develop acquired resistance to imatinib, with a median time
o resistance of two years. Patients with metastatic GIST treated
ith imatinib have a median overall survival of ﬁve years [14].
In a phase III randomized controlled trial, Demetri et al. found
hat patients with advanced GIST resistant or intolerant to ima-
inib treated with sunitinib experienced a longer median time to
rogression (27.3 weeks vs. 6.4 weeks), longer progression-free
urvival (24.1 weeks vs. 6.0 weeks), and improved overall survival
ompared to the placebo group [15].
In a multicenter, randomized placebo-controlled trial in which
atients with progression of metastatic colorectal cancer despite
eceiving standard therapy, Grothey et al. found that patients
ho received regorafenib had a median overall survival of 6.4
onths compared to 5.0 months in the placebo group [16]. Adverse
vents attributable to regorafenib include hand-foot skin reaction,
atigue, diarrhea, hypertension, and rash, anorexia, and mucositis
16,17]. In a randomized, double-blind, placebo-controlled trial in
99 patients with advanced GIST and failure of imatinib and suni-
inib to control disease, the GRID trial found that patients who
eceived regorafenib had a longer median progression-free survival
ompared to patients who received a placebo (4.8 months vs. 0.9
onths), and 75.9% were found to have partial response or stable
isease while on regorafenib [18]. George et al. similarly found that
atients with metastatic GIST who were started on regorafenib had
 median progress-free survival of 10.0 months. Twenty-six of 33
atients with metastatic GIST that failed treatment with imatinib
nd sunitinib were found to have partial response (four patients) or
table disease (22 patients) after at least two cycles of regorafenib
19].
A retrospective study examining surgical resection in patients
ith metastatic GIST concluded that survival in patients who
nderwent metastasectomy was associated with disease respon-
iveness while on imatinib therapy. Patients with disease that
emained stable or responded to imatinib treatment were found toPEN  ACCESS
gery Case Reports 29 (2016) 172–175
have prolonged overall survival after undergoing metastasectomy
[13].
4. Conclusion
This case documents the ﬁrst reported case of a GIST with metas-
tasis to the penis. The patient presented in this case report was
found to have a rectal GIST on screening colonoscopy. This lesion
subsequently has been found to metastasize to the penis and right
hip. Analysis of biopsies of these lesions demonstrates an exon 11
activating KIT mutation. Heinrich et al. evaluated 127 patients diag-
nosed with GISTs for mutations of KIT or PDGFRA and correlated
the patients’ mutation type to their respective clinical outcome.
Patients with an exon 11 activating mutation of KIT were found to
have a higher partial response rate to imatinib (83.5% vs. 47.8%)
and overall survival (p = 0.0034) compared to patients with exon 9
KIT mutations [20]. Partial response to imatinib was initially seen
in both the primary GIST and corpus cavernosum metastatic lesion
of the patient described here. Despite continued use of imatinib,
metastatectomy, and treatment with sunitinib, the patient has
unfortunately experienced progression of his metastatic disease.
Patients with primary GIST who underwent complete resection are
reported to have a median survival of 66 months [12]. Due to the
progression of our patient’s metastatic disease despite treatment
with imatinib and sunitinib, treatment with regorafenib has been
recommended.
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